Burgdorf – Ypsomed, Abbott and CamDiab will work to accelerate the development of an automated insulin delivery system for people living with diabetes. The system is being designed to include Abbott’s FreeStyle Libre 3 sensor, CamDiab’s CamAPS FX algorithm, and Ypsomed’s mylife YpsoPump. The partnership demonstrates the companies’ collective desire to drive integrated solutions to help people with diabetes better manage their condition and improve health outcomes.

Ypsomed partners with CamDiab Ltd to drive on smartphone based adaptive automated insulin delivery (AID)

Burgdorf – Ypsomed partners with CamDiab Ltd, the developer of CamAPS FX, an app to manage glucose levels via insulin pumps using an adaptive, hybrid closed-loop approach. During the first half of 2022, this easy-to-use loop solution will be launched for the mylife YpsoPump system, starting in selected major countries in Europe and followed by other territories in the course of the year. Patients can then connect the mylife YpsoPump system to the mylife CamAPS FX Android mobile application and are enabled to algorithm-based insulin delivery support including bolus from the personal smartphone.

Sébastien Delarive to become new Senior Vice President Diabetes Care
Sébastien Delarive to become new Senior Vice President Diabetes Care.

Press Releases Ypsomed Group

Burgdorf – With the aim of focusing on changing customer needs, Ypsomed is stepwise optimizing the organisation of the business units and the Management Board.

World’s first autoinjector with fully integrated connectivity

Press Releases Ypsomed Group

Burgdorf – Ypsomed has introduced the world’s first autoinjector for prefilled syringes with integrated connectivity. The YpsoMate On combines the advantages of the proven YpsoMate autoinjector with the options of digital therapy support. The YpsoMate On follows an eco-design principle which allows easy recycling of electronic components and encourages the use of sustainable components.